Qi Chen

Qi Chen

Auto-generated profile, based on publicly available information

Qi Chen

Department of Urology, RenJi Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
QCQi Chen
Qi Chen
CJChenwei Jiang
Chenwei Jiang
XDXinxing Du
Xinxing Du
MTMinglu Tang
Minglu Tang
QSQi Shang
Qi Shang
JPJiahua Pan
Jiahua Pan
Personalized vaccines demonstrate remarkable potential in leveraging tumor-specific adaptive immunity for cancer therapy. Nevertheless, current platforms face persistent challenges, including premature systemic clearance and imprecise antigen-presenting cell targeting, culminating in transient and inefficient antitumor immunity. Furthermore, the technical complexity, extended timelines, and prohibitive costs required for tumor-specific neoantigen identification continue to impede the clinical translation of personalized cancer vaccines. Here, we report a tumor-derived extracellular vesicle-based scaffold vaccine that elicits robust and durable antitumor immunity for personalized cancer immunotherapy. Following subcutaneous administration, the in situ-formed hydrogel vaccine serves as a sustained reservoir for tumor-derived extracellular vesicle antigens and adjuvants while recruiting antigen-presenting dendritic cells to accumulate within the scaffold. Upon exposure to this antigen-rich depot, immature dendritic cells undergo efficient activation, with subsequently matured dendritic cells migrating to draining lymph nodes, where they induce potent and persistent tumor-specific CD8+ T-cell responses that suppress tumor progression across multiple murine models. Specifically, when using tumor-derived extracellular vesicles isolated from surgically excised tumor tissues, the patient-tailored vaccines demonstrate remarkable efficacy in preventing postoperative recurrence. Our findings validate the robust and durable therapeutic efficacy of this vaccine platform, highlighting its potential as a customizable strategy for personalized cancer immunotherapy.

4 September 2026 in Science Advances
Verified
Journal Article
Open access
CJChenwei Jiang
Chenwei Jiang
MTMinglu Tang
Minglu Tang
MGMingmei Guo
Mingmei Guo
QSQi Shang
Qi Shang
QCQi Chen
Qi Chen
FWFeihu Wang
Feihu Wang
The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has not been translated to solid tumors, primarily due to inadequate T cell infiltration and an immunosuppressive tumor microenvironment that drives T cell exhaustion. To address these challenges, we developed a tailored immunomodulatory drug-drug conjugate-based hydrogelator for the localized delivery of CAR-T cells targeting solid tumors. This hydrogel forms an in situ scaffold that serves as a sustained-release reservoir, enabling continuous co-delivery of CAR-T cells along with immunomodulatory agents—NLG919 (an IDO-1 inhibitor) and D PPA-1 (a PD-L1 antagonistic peptide)—to synergistically remodel the immunosuppressive tumor microenvironment and promote robust tumor recognition and elimination. Notably, this approach significantly enhances CAR-T cell infiltration and persistence, stimulates a potent endogenous tumor-specific immune response, while also establishing long-lasting immunological memory. In murine models of aggressive melanoma, metastatic breast cancer, and postoperative glioma, a single local administration of the hydrogel resulted in significant suppression of tumor growth, rechallenge, metastasis and recurrence. By integrating localized CAR-T cell delivery with in situ immune reprogramming, this system represents a versatile and clinically translatable platform that substantially improves the efficacy of CAR-T cell therapy against solid tumors.